News

Danville organization invests in Blacksburg’s CytoRecovery medical cell sorting company

Danville’s investment might mean a CytoRecovery presence in Danville, such as office operations or an internship at Danville Community College. CytoRecovery’s cell sorting could improve understanding of disease and development of drugs.

CytoRecovery, an early-stage company that invented and patented less invasive cell sorting, will be able to bring its cell research platform to market after an investment from a Danville-based organization.

This means Blacksburg-based CytoRecovery could have a presence in Danville, according to Stephen Turner, the company’s CEO.

“CytoRecovery looks forward to participating in the Danville economy, and is currently reviewing several options to do so, including establishing branch office operations and a collaboration to develop a life science internship program with Danville Community College,” Turner said in an email.

Danville’s The Launch Place, an organization that works to support entrepreneurs and raise capital, announced Dec. 1 an investment of $250,000 in Cyto Recovery.

This funding “will help CytoRecovery commercialize its flagship cell sorting platform for medical research,” a release said.

Specifically, CytoRecovery will bring its Cyto R1 platform to the market after five years of development.

This product “improves the speed and precision of the sorting, enrichment and recovery of live cells from tissue and other biological samples,” the release said. “Its technology can quickly isolate, enrich and recover rare, distinct cell populations, enabling their downstream analysis and therapeutic response.”

This investment comes after the company’s inaugural sale of Cyto R1 to University of California at Irvine researchers in September.

“Having just installed our first system at a major California-based stem cell research center, we have a growing pipeline of prospective customers,” Turner said in the release.

CytoRecovery’s faster and less invasive cell sorting could improve understanding of disease, development of drugs, and determination of effective therapies.

The Launch Place team chose CytoRecovery for this funding because they believed in both the technology and in Turner himself, who has founded several life science companies, said the release.

CytoRecovery’s platform outperforms existing cell separation methods, said Eva Doss, president and CEO of The Launch Place.

“The technology also enables new possibilities in cell research by having broad applications in the fields of oncology, regenerative medicine, hyper-personalized medicine, and pharmaceutical research and development,” Doss said in the release.

The two organizations have an existing relationship. In 2018, CytoRecovery received a $75,000 investment from The Launch Place, which guided the startup’s development and provided instructions to other sources of funding and potential customers, the release said.

A CytoRecovery branch office operation in Danville would be its first location outside of Blacksburg.

Read more here.

Recent News

04/15/2026

Gov. Spanberger and Homegrown Innovator Agrospheres Celebrate Launch of Virginia’s new Biomanufacturing Facility

AgroSpheres, Inc., a Charlottesville-based agricultural biotechnology company, officially opened its first commercial biomanufacturing facility, representing a milestone for AgroSpheres and the biotech ecosystem. Speakers at the ribbon-cutting ceremony included: Virginia Governor Abigail Spanberger, AgroSpheres co-founders CEO Payam Pourtaheri and CTO Ameer Shakeel, Albemarle County Chair of the Board of Supervisors Ned Gallaway, President of the

04/08/2026

Likarda and The Tiny Cargo Company Announce Strategic Partnership to Advance Next-Generation Delivery of Biologics, Peptides and Small Molecules

Likarda, Inc., a leader in hydrogel-based drug delivery technologies, today announced a strategic partnership with Tiny Cargo, an innovator in extracellular vesicle (EV) delivery systems. The collaboration will focus on advancing the delivery of biologics and small molecules by integrating Likarda’s Core-Shell Spherification® (CSS®) platform with Tiny Cargo’s vesicle-based technologies. The partnership is designed to

04/08/2026

ReAlta Life Sciences Closes Oversubscribed $40 Million Financing Round to Advance Pegtarazimod Phase 2 Program in Hypoxic Ischemic Encephalopathy (HIE)

ReAlta Life Sciences Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to potentially revolutionize the treatment of inflammatory disorders, today announced the closing of an oversubscribed $40 million financing. This brings the total capital raised to date to more than $150 million.